



PTC Therapeutics, Inc.
Investor Relations Department
100 Corporate Ct.
South Plainfield, NJ 07080
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: PTCT

Last Trade:	17.85
Trade Time:	4:00 PM ET Jun 27, 2017
Change:	-0.54 (-2.936%)
Day Range	17.53 - 18.69
52-Week Range	4.03 - 18.67
Volume	770,952

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

PTC Therapeutics, Inc. is committed to serving the interests of our shareholders. This part of our website includes corporate governance documents, press releases, financial information and other documents to help shareholders better understand who we are and what we do.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jun 22, 2017

[New Analyses of Translarna™ \(ataluren\)
Data from ACT DMD Presented at the 12th
Annual European Pediatric Neurology Society
Congress](#)

Jun 6, 2017

[PTC Therapeutics Announces FDA Advisory
Committee Meeting for Ataluren for the
Treatment of Nonsense Mutation
Dystrophinopathy](#)

Jun 5, 2017

[PTC Therapeutics Announces Executive
Promotions](#)

Jun 2, 2017

[PTC Therapeutics Reports Inducement
Grants Under Nasdaq Listing Rule 5635\(c\)\(4\)](#)

May 23, 2017

[New Analysis of ACT DMD Placebo Data on
Corticosteroids Presented at International
Society for Pharmacoeconomics and
Outcomes Research 22nd Annual
International Meeting](#)

Financials [\[View all \]](#)

Mar 16, 2017

[Annual Report \(10-K\)](#)

Apr 28, 2017

[Proxy Statement \(DEF 14A\)](#)

May 8, 2017

[Quarterly Report \(10-Q\)](#)

Nov 3, 2016

[Quarterly Report \(10-Q\)](#)

Aug 4, 2016

[Quarterly Report \(10-Q\)](#)